Compare Stocks → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CRBPNASDAQ:DERMNASDAQ:NEPTNASDAQ:OVASNASDAQ:PTGX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBPCorbus Pharmaceuticals$37.03-0.3%$34.63$3.03▼$49.87$389.19M2.46813,919 shs20,420 shsDERMJourney Medical$3.74-3.1%$3.87$1.02▼$8.11$74.54M0.8193,188 shs40,518 shsNEPTNeptune Wellness Solutions$0.39$0.19▼$28.00$906K2.19462,687 shs2.25 million shsOVASOvaScience$3.27-2.4%$12.74$0.66▼$1.52$117.16M3.11163,131 shs682,179 shsPTGXProtagonist Therapeutics$25.46-0.4%$28.56$13.72▼$33.34$1.48B2.01709,461 shs55,183 shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBPCorbus Pharmaceuticals-9.63%-2.60%-10.72%+436.99%+209.67%DERMJourney Medical+1.58%-11.87%+3.21%+385,999,900.00%+385,999,900.00%NEPTNeptune Wellness Solutions0.00%0.00%0.00%-60.00%-99.19%OVASOvaScience-2.39%-12.10%-15.50%-21.39%-11.62%PTGXProtagonist Therapeutics-2.07%-8.29%-10.15%+6.72%+10.17%A new way to collect income from stocks (Ad)Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRBPCorbus Pharmaceuticals4.4014 of 5 stars3.53.00.04.72.63.30.6DERMJourney Medical2.3141 of 5 stars3.53.00.00.01.82.50.6NEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/AN/AN/AN/AOVASOvaScienceN/AN/AN/AN/AN/AN/AN/AN/APTGXProtagonist Therapeutics0.9031 of 5 stars3.51.00.00.00.62.50.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRBPCorbus Pharmaceuticals3.00Buy$52.0040.43% UpsideDERMJourney Medical3.00Buy$8.50127.27% UpsideNEPTNeptune Wellness SolutionsN/AN/AN/AN/AOVASOvaScienceN/AN/AN/AN/APTGXProtagonist Therapeutics3.00Buy$36.0041.40% UpsideCurrent Analyst RatingsLatest DERM, OVAS, PTGX, CRBP, and NEPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/13/2024CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$51.00 ➝ $58.003/6/2024CRBPCorbus PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$4.00 ➝ $46.002/28/2024PTGXProtagonist TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$34.00 ➝ $37.002/28/2024PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.002/16/2024DERMJourney MedicalAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.501/29/2024CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$20.00 ➝ $51.00(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRBPCorbus Pharmaceuticals$880K442.26N/AN/A($1.56) per share-23.74DERMJourney Medical$79.18M0.94$0.18 per share20.97$1.05 per share3.56NEPTNeptune Wellness Solutions$52.62M0.00N/AN/A($91.90) per share0.00OVASOvaScience$290K404.01N/AN/A$1.80 per share1.82PTGXProtagonist Therapeutics$60M24.73N/AN/A$5.84 per share4.36Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRBPCorbus Pharmaceuticals-$44.60M-$10.37N/AN/AN/AN/A-920.31%-111.56%5/14/2024 (Estimated)DERMJourney Medical-$3.85M-$0.35N/AN/AN/A-4.87%-34.08%-5.00%5/27/2024 (Estimated)NEPTNeptune Wellness Solutions-$60.46M-$106.72N/AN/AN/A-128.13%N/A-141.94%7/15/2024 (Estimated)OVASOvaScience-$50.97MN/A0.00∞N/A-10,128.37%-47.06%-42.39%N/APTGXProtagonist Therapeutics-$78.96M-$1.49N/AN/AN/AN/A-27.49%-25.30%5/2/2024 (Estimated)Latest DERM, OVAS, PTGX, CRBP, and NEPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023DERMJourney MedicalN/A-$0.12-$0.12-$0.12$15.80 million$15.26 million3/12/2024Q4 2023CRBPCorbus Pharmaceuticals-$2.36-$1.81+$0.55-$1.81N/AN/A2/27/202412/31/2023PTGXProtagonist Therapeutics$0.05$0.44+$0.39$0.44$60.00 million$60.00 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/ADERMJourney MedicalN/AN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/AOVASOvaScienceN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRBPCorbus PharmaceuticalsN/A0.740.74DERMJourney Medical0.721.351.10NEPTNeptune Wellness SolutionsN/A0.230.10OVASOvaScienceN/A12.6212.62PTGXProtagonist TherapeuticsN/A16.7116.71OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRBPCorbus Pharmaceuticals64.64%DERMJourney Medical7.25%NEPTNeptune Wellness Solutions14.44%OVASOvaScience22.52%PTGXProtagonist Therapeutics98.63%Insider OwnershipCompanyInsider OwnershipCRBPCorbus Pharmaceuticals4.00%DERMJourney Medical19.42%NEPTNeptune Wellness Solutions5.10%OVASOvaScience7.40%PTGXProtagonist Therapeutics5.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCRBPCorbus Pharmaceuticals1910.51 million10.09 millionOptionableDERMJourney Medical2019.93 million16.06 millionN/ANEPTNeptune Wellness Solutions584.53 million4.30 millionNot OptionableOVASOvaScienceN/A35.83 millionN/ANot OptionablePTGXProtagonist Therapeutics11258.28 million55.36 millionOptionableDERM, OVAS, PTGX, CRBP, and NEPT HeadlinesSourceHeadlineProtagonist Therapeutics (NASDAQ:PTGX) Stock Price Passes Below 50-Day Moving Average of $28.56americanbankingnews.com - April 18 at 4:26 AMVanguard Group Inc. Raises Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)marketbeat.com - April 9 at 4:08 AMAll You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buyzacks.com - April 5 at 1:01 PMProtagonist Pictures’ Len Rowles to join development fund Climate Spring (exclusive)screendaily.com - April 3 at 8:30 AMInsider Selling: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CEO Sells 25,000 Shares of Stockinsidertrades.com - April 3 at 4:58 AMProtagonist Therapeutics Inc CEO Sells 25,000 Sharesfinance.yahoo.com - April 3 at 3:29 AMShareholders have faith in loss-making Protagonist Therapeutics (NASDAQ:PTGX) as stock climbs 3.7% in past week, taking five-year gain to 135%finance.yahoo.com - April 1 at 4:10 PMProtagonist Therapeutics Earns ‘Buy’ Rating on Strong Clinical Progress and Strategic Partnershipsmarkets.businessinsider.com - March 27 at 11:05 AMProtagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Dataaccesswire.com - March 26 at 7:00 AMWall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a Betzacks.com - March 18 at 10:56 AMProtagonist Therapeutics, Inc.: Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takedafinanznachrichten.de - March 18 at 9:09 AMWalleye Capital LLC Grows Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)marketbeat.com - March 18 at 4:17 AMPTGX Apr 2024 15.000 callfinance.yahoo.com - March 15 at 11:37 PMPTGX Apr 2024 30.000 putfinance.yahoo.com - March 15 at 11:37 PM4 Stocks to Buy for Attractive Earnings Accelerationzacks.com - March 15 at 7:16 AMThe People's Market owner snaps up former Protagonist space in heart of NoDa for barbizjournals.com - March 12 at 4:15 PMBuy Rating Affirmed for Protagonist Therapeutics on Strong Phase 2b Results and Strategic Phase 3 Dosing of JNJ-2113markets.businessinsider.com - March 12 at 12:49 AMStrong Buy Rating for Protagonist Therapeutics on JNJ-2113’s Promising Psoriasis Treatment Efficacy and Financial Outlookmarkets.businessinsider.com - March 11 at 8:33 AMProtagonist Therapeutics to Participate in Upcoming Investor Conferencesaccesswire.com - March 6 at 4:05 PM4 Must-Buy Stocks for Remarkable Earnings Accelerationzacks.com - March 4 at 8:06 AMThis Just In: Analysts Are Boosting Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Outlook for This Yearfinance.yahoo.com - March 3 at 10:14 AMEarnings Update: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Just Reported And Analysts Are Boosting Their Estimatesfinance.yahoo.com - March 2 at 8:20 AMEarnings Estimates Moving Higher for Protagonist Therapeutics (PTGX): Time to Buy?zacks.com - March 1 at 1:21 PMAre You Looking for a Top Momentum Pick? Why Protagonist Therapeutics (PTGX) is a Great Choicezacks.com - March 1 at 1:01 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCorbus PharmaceuticalsNASDAQ:CRBPCorbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Journey MedicalNASDAQ:DERMJourney Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Zilxi, a topical minocycline treatment for inflammatory lesions; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.Neptune Wellness SolutionsNASDAQ:NEPTNeptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada. OvaScienceNASDAQ:OVASMillendo Therapeutics, Inc. is a biopharmaceutical company, which engages in seeking distinct and transformative treatments where there is a significant unmet medical need. The company was founded by Julia C. Owens in January 2012 and is headquartered in Ann Arbor, MI.Protagonist TherapeuticsNASDAQ:PTGXProtagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.